Development of Host Immune Response to Bacteriophage in a Lung Transplant Recipient on Adjunctive Phage Therapy for a...

Area of Science:

• Immunology
• Microbiology
• Infectious Diseases

Background:

• Bacteriophage therapy is a promising alternative for treating antibiotic-resistant bacterial infections.
• The human immune response to bacteriophage therapy remains largely uncharacterized.
• Pseudomonas aeruginosa is a common cause of difficult-to-treat lung infections, particularly in immunocompromised individuals.

Purpose of the Study:

• To investigate the human immune response during adjunctive bacteriophage therapy.
• To characterize the development of phage-specific immune markers in a clinical setting.
• To assess the safety and efficacy of bacteriophage therapy in a lung transplant recipient.

Main Methods:

• Case report of a lung transplant recipient with multidrug-resistant Pseudomonas aeruginosa pneumonia.
• Administration of adjunctive bacteriophage therapy.
• Monitoring of phage-specific CD4 T cell responses.
• Measurement of phage-specific immunoglobulin G (IgG) and neutralizing antibodies.

Main Results:

• Successful clinical treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia.
• Development of detectable phage-specific CD4 T cell responses.
• Rising levels of phage-specific IgG and neutralizing antibodies were observed.
• Phage-specific immune responses did not preclude successful clinical outcome.

Conclusions:

• Adjunctive bacteriophage therapy can elicit robust, specific immune responses in humans.
• The development of phage-specific immunity does not necessarily contraindicate successful therapeutic outcomes.
• Further research is warranted to fully understand the immunomodulatory effects of bacteriophage therapy.